Document is current
Any future updates will be listed below
-
Authors
Furukawa, Kenichiro
Hatakeyama, Keiichi
Terashima, Masanori https://orcid.org/0000-0002-2967-8267
Fujiya, Keiichi
Tanizawa, Yutaka
Bando, Etsuro
Sugino, Takashi
Urakami, Kenichi
Naito, Tateaki
Kagawa, Hiroyasu
Yamaguchi, Ken
- License Information
-
More Information
Article History
Received: 11 October 2022
Accepted: 14 November 2022
First Online: 2 December 2022
Declarations
:
: These present studies were each approved by the institutional review board of Shizuoka Cancer Center (approval no. 30-43-2019-1-3, 2019-4-2019-1-2).
: Written informed consent was not needed for Patient 1, because the patient is dead. Written informed consent was obtained from Patient 2 for the publication of this case report and any accompanying images. A copy of the written informed consent is available for review by the Editor-in-Chief of this journal.
: MT has received honorarium from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squib Japan K.K., Yakult Honsha Co., Ltd, Takeda Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Pfizer Japan Inc., Daiichi Sankyo Ltd., Johnson and Johnson K.K., Medtronic Japan Co., Ltd., Intuitive Japan Inc., and Olympus Co., Ltd. EB has received honorarium from EIZO Corporation, TERUMO CORPORATION, and EIZAI. TN has received honorarium from Ono Pharmaceutical Co., Ltd., and research funding from Otsuka Pharmaceutical Co., Ltd.
